CMEdiscovery.com
pills monotherapy brain
home faculty accreditation View Program post-test contact

Monograph

Download PDF

References

  1. Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav. 2005;7(Suppl 1):S1-S64.
  2. Kanner AM, Balabanov AJ. The use of monotherapy in patients with epilepsy: an appraisal of the new antiepileptic drugs. Curr Neurol Neurosci Rep. 2005;5:322-328.
  3. Vazquez B. Monotherapy in epilepsy. Role of the newer antiepileptic drugs. Arch Neurol. 2004;61:1361-1365.
  4. Baulac M. Rational conversion from antiepileptic polytherapy to monotherapy. Epileptic Disord. 2003;5:125-132.
  5. Collaborative Group for the Study of Epilepsy. Prognosis of epilepsy in newly referred patients: a multicenter prospective study of the effects of monotherapy on the long-term course of epilepsy. Epilepsia. 1992;33:45-51.
  6. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314-319.
  7. Marson AG, Kadir ZA, Hutton JL, et al. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia. 1997;38:859-880.
  8. Sirven JI. Antiepileptic drug therapy for adults: when to initiate and how to choose. Mayo Clin Proc. 2002;77:1367-1375.
  9. Devinsky O, Westbrook L, Cramer J, et al. Risk factors for poor health-related quality of life in adolescents with epilepsy. Epilepsia. 1999;40:1715-1720.
  10. Gilliam F. The impact of epilepsy on subjective health status. Curr Neurol Neurosci Rep. 2003;3:357-362.
  11. Bourgeois BFD. Combination Drug Therapy (Monotherapy Versus Polytherapy). In Pellock JM, Dodson WE, and Bourgeois BFD, eds. Pediatric Epilepsy Diagnosis and Therapy. 2nd ed. New York, NY: Demos Medical Publishing, Inc; 2001:563:568.
  12. Bourgeois BF. Problems of combination drug therapy in children. Epilepsia. 1988;29(Suppl 3):S20-S24.
  13. Hank NC, Chung SS, Treiman DM. Is monotherapy preferred by patients whose seizures remain well controlled? Epilepsia. 2004;45(Suppl 7):281.
  14. Guberman A. Monotherapy or polytherapy for epilepsy. Can J Neurol Sci. 1998;25:S3-S8.
  15. Pirio Richardson S, Farias ST, Lima AR 3rd, et al. Improvement in seizure control and quality of life in medically refractory epilepsy patients converted from polypharmacy to monotherapy. Epilepsy Behav. 2004;5:343-347.
  16. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Resister. J Neurol Neurosurg Psychiatry. 2006;77:193-198.
  17. Leavitt AM, Yerby M, Robinson NM. Epilepsy and pregnancy: developmental outcomes of children of mothers with epilepsy. Available at http://www.seizures.net/articles_epilepsy/DevelopmentalOutcomes.html Accessed on September 24, 2006.
  18. Cloyd J, Hauser W, Towne A, et al. Epidemiological and medical aspects of epilepsy in the elderly. Epilepsy Res. 2006;68(Suppl1):S39-S48.
  19. Stephen LJ. Drug treatment of epilepsy in elderly people: focus on valproic acid. Drugs Aging. 2003;20:141-152.
  20. Martin R, Vogtle L, Gilliam F, et al. Health-related quality of life in senior adults with epilepsy: what we know from randomized clinical trials and suggestions for future research. Epilepsy Behav. 2003;4:626-634.
  21. Shinnar S, Pellock JM. Update on the epidemiology and prognosis of pediatric epilepsy. J Child Neurol. 2002;17(Suppl 1):S4-S17.
  22. Pellock JM. Defining the problem: psychiatric and behavioral comorbidity in children and adolescents with epilepsy. Epilepsy Behav. 2004;5(Suppl 3):S3-S9.
  23. Sankar RS. Initial treatment of epilepsy with antiepileptic drugs. Neurology. 2004;63(Suppl 4):S30-S39.
  24. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med. 1992;327:765-771.
  25. Mattson RH, Cramer JA, Collins JF. A comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Eng J Med. 1985;313:145-151.
  26. Heller AJ, Chesterman P, Elwes RD, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomized comparative monotherapy trial. J Neurol Neurosurg Psychiatry. 1995;58:44-50.
  27. Hitiris N, Brodie MJ. Modern antiepileptic drugs: guidelines and beyond. Curr Opin Neurol. 2006;19:175-180.
  28. Welty TE, Privitera M, Shukla R. Increased seizure frequency associated with felbamate withdrawal in adults. Arch Neurol. 1998;55:641-645.
  29. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2004;45:401-409.
  30. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2004;45:410-423.
  31. Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. 1997;27:195-204.
  32. Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. 1997;26:451-460.
  33. Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed previously untreated epilepsy. Epilspsy Res. 1989;3:70-76.
  34. Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology. 1999;52:732-737.
  35. Beydoun A, Sachdeo RC, Rosenfeld WE, et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology. 2000;54:2245-2251.
  36. Beydoun A, Sachdeo RC, Kutluay E, et al. Sustained efficacy and long-term safety of oxcarbazepine: one-year open-label extension of a study in refractory partial epilepsy. Epilepsia. 2003;44:1160-1165.
  37. Kothare SV, Khurana DS, Mostofi N, et al. Oxcarbazepine monotherapy in children and adolescents: a single-center clinical experience. Pediatr Neurol. 2006;35:235-239.
  38. Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997;27:205-213
  39. Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand. 2003;107:165-175.
  40. Wheless JW, Neto W, Wang S, et al. Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in children with newly diagnosed epilepsy. J Child Neurol. 2004;19:135-141.
  41. Gilliam, FG, Veloso F, Bomhof MA, et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology. 2003;60:196-202.
  42. Guerrini R, Carpay J, Groselj J, et al. Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting. Seizure. 2005;14:371-380.
  43. Valencia I, Rons C, Kothare SV, et al. Efficacy and tolerability of topiramate in children younger than 2 years old. J Child Neurol. 2005;20:667-669.
  44. Kwon YS, Jun YH, Hong YJ, et al. Topiramate monotherapy in infantile spasm. Yonsei Med J. 2006;47:498-504.
  45. Groselj J, Guerrini R, Van Oene J, et al. Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy. Acta Neurol Scand. 2005;112:144-150.
  46. Sachdeo R, Beydoun A, Schachter S, et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology. 2001;57:864-871.
  47. Dorado R, Gomez-Arguelles JM, Herrera A, et al. Topiramate in comorbid disorders: epilepsy and migraine. Rev Neurol. 2006;43:193-196.
  48. The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med. 1993;328:29-33.
  49. Sachdeo R, Kramer LD, Rosenberg A, et al. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol. 1992;32:386-392.
  50. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet. 1995;345:476-479.
  51. Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia. 1999;40:601-607.
  52. Brodie MJ, Chadwick DW, Anhut H, et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia. 2002;43:993-1000.
  53. Jarrar RG, Buchhalter JR. Therapeutics in pediatric epilepsy, Part 1: The new antiepileptic drugs and the ketogenic diet. Mayo Clin Proc. 2003;78:359-370.
  54. Mohanraj R, Brodie MJ. Pharmacological outcomes in newly diagnosed epilepsy. Epilepsy Behav. 2005;6:382-387.
  55. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64:1868-1973.
  56. Frank LM, Enlow T, Holmes GL, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia. 1999;40:973-979.
  57. Coppola G, Auricchio G, Federico R, et al. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia. 2004;45:1049-1053.
  58. Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology. 1998;51:1018-1025.
  59. Edwards KR, Sackellares JC, Vuong A, et al. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy Behav. 2001;2:28-36.
  60. Salpekar JA, Conty JA, Doss W, et al. Clinical experience with anticonvulsant medication in pediatric epilepsy and comorbid bipolar spectrum disorder. Epilepsy Behav. 2006;9:327-334.
  61. Beydoun A. Monotherapy trials with gabapentin for partial epilepsy. Epilepsia. 1999;40(Suppl 6):S13-S16.
  62. Brodie MJ, Chadwick DW, Anhut H, et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia. 2002;43:993-1000.
  63. Bergy GK, Morris HH, Rosenfeld W, et al. Gabapentin monotherapy, I: An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures: the US Gabapentin Study Group 88/89. Neurology. 1997;49:739-745.
  64. Beydoun A, Fischer J, Labar DR, et al. Gabapentin monotherapy, II: A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures: the US Gabapentin Study Group 82/83. Neurology. 1997;49:746-752.
  65. Trudeau V, Myers S, LaMoreaux L, et al. Gabapentin in naive childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol. 1996;22:470-475.
  66. Alsaadi TM, Thieman C, Zusman EE. Levetiracetam monotherapy for adults with localization-related epilepsy. Epilepsy Behav. 2002;3:471-474.
  67. Alsaadi TM, Thieman C. Levetiracetam monotherapy for newly diagnosed epilepsy patients. Seizure. 2003;12:154-156.
  68. Alsaadi TM, Koopmans S, Apperson M, et al. Levetiracetam monotherapy for elderly patients with epilepsy. Seizure. 2004;13:58-60.
  69. Ben-Menachem E, Brodie MJ, Perucca E. Efficacy of levetiracetam monotherapy; Randomized double-blind head-to-head comparison with carbamazepine-CR in newly diagnosed epilepsy patients with partial onset or generalized tonic-clinic seizures. 58th Annual Meeting of the American Academy of Neurology. San Diego, CA; April 1-8, 2006. Abstract [S09.006].
  70. Lamotrigine versus levetiracetam in the initial monotherapy of epilepsy. Available at http://www.clinicaltrials.gov/ct/show/NCT00242606. Accessed on September 15, 2006.
  71. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia. 2000;41:1276-1283.
  72. Kavoussi R. Pregabalin: From molecule to medicine. Eur Neuropsychopharmacol. 2006;16(Suppl 2):S128-S133.
  73. Schachter SC. Tiagabine monotherapy in the treatment of partial epilepsy. Epilepsia. 1995;36(Suppl 6):S2-S6.
  74. Aikia M, Jutila L, Salmenpera T, et al. Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: pooled analysis of two long-term, randomized, follow-up studies. Epilepsia. 2006;47:1121-1127.
  75. Tosches WA, Tisdell J. Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide. Epilepsy Behav. 2006;8:522-526.
  76. Newmark ME, Dubinsky S. Zonisamide monotherapy in a multi-group clinic. Seizure. 2004;13:223-225.
  77. Kothare SV, Valencia I, Khurana DS, et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord. 2004;6:267-270.
  78. Kothare SV, Kaleyias J, Mostofi N, et al. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Pediatr Neurol. 2006;34:351-354.




Printer settings may vary. Please use landscape layout option.



CMEdiscovery.com
Copyright © 2006 Scinexa, LLC / CMEdiscovery.com. All rights reserved.